Edwards Lifesciences (EW) Cost of Revenue (2009 - 2026)

Edwards Lifesciences' Cost of Revenue history runs 18 years deep, the most recent figure standing at $362.6 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 20.23% year-over-year to $362.6 million in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 23.23% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 19.39% from the prior year.
• Cost of Revenue grew to $362.6 million in Q1 2026 per EW's latest filing, from $343.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $362.6 million in Q1 2026 and bottomed at -$98.8 million in Q4 2022.
• The 5-year median for Cost of Revenue is $286.9 million (2024), against an average of $272.1 million.
• Across the five-year window, Cost of Revenue tumbled 131.92% in 2022 and jumped 354.05% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at -$98.8 million in 2022, then jumped by 354.05% to $251.0 million in 2023, then climbed by 16.41% to $292.2 million in 2024, then climbed by 17.39% to $343.0 million in 2025, then rose by 5.71% to $362.6 million in 2026.
• Per Business Quant, the three latest EW Cost of Revenue figures stand at $362.6 million (Q1 2026), $343.0 million (Q4 2025), and $345.2 million (Q3 2025).